Malignant Infratentorial Neoplasm — Trials

Malignant Infratentorial Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

302 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 99
Recruiting: 50
Ph III recruiting: 3
Growth YoY: —
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (46)

clinicaltrialsPublishedShowing 101–117 of 117 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00063973	Cilengitide in Treating Children With Refractory Primary Brain Tumors	completed	Phase 1	24	National Cancer Institute (NCI)NIH	1	Sep 30, 2013	clinicaltrials
NCT00100880	Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors	completed	Phase 1	45	National Cancer Institute (NCI)NIH	1	Sep 30, 2013	clinicaltrials